Potassium in PDB 4xdl: Crystal Structure of Human Two Pore Domain Potassium Ion Channel TREK2 (K2P10.1) in Complex with A Brominated Fluoxetine Derivative.
Protein crystallography data
The structure of Crystal Structure of Human Two Pore Domain Potassium Ion Channel TREK2 (K2P10.1) in Complex with A Brominated Fluoxetine Derivative., PDB code: 4xdl
was solved by
A.Mackenzie,
A.C.W.Pike,
Y.Y.Dong,
S.Mukhopadhyay,
G.F.Ruda,
P.E.Brennan,
C.H.Arrowsmith,
A.M.Edwards,
C.Bountra,
N.A.Burgess-Brown,
E.P.Carpenter,
Structural Genomics Consortium (Sgc),
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
Resolution Low / High (Å)
|
35.00 /
3.50
|
Space group
|
P 21 21 21
|
Cell size a, b, c (Å), α, β, γ (°)
|
101.710,
109.840,
166.740,
90.00,
90.00,
90.00
|
R / Rfree (%)
|
23.5 /
26.3
|
Other elements in 4xdl:
The structure of Crystal Structure of Human Two Pore Domain Potassium Ion Channel TREK2 (K2P10.1) in Complex with A Brominated Fluoxetine Derivative. also contains other interesting chemical elements:
Potassium Binding Sites:
The binding sites of Potassium atom in the Crystal Structure of Human Two Pore Domain Potassium Ion Channel TREK2 (K2P10.1) in Complex with A Brominated Fluoxetine Derivative.
(pdb code 4xdl). This binding sites where shown within
5.0 Angstroms radius around Potassium atom.
In total 6 binding sites of Potassium where determined in the
Crystal Structure of Human Two Pore Domain Potassium Ion Channel TREK2 (K2P10.1) in Complex with A Brominated Fluoxetine Derivative., PDB code: 4xdl:
Jump to Potassium binding site number:
1;
2;
3;
4;
5;
6;
Potassium binding site 1 out
of 6 in 4xdl
Go back to
Potassium Binding Sites List in 4xdl
Potassium binding site 1 out
of 6 in the Crystal Structure of Human Two Pore Domain Potassium Ion Channel TREK2 (K2P10.1) in Complex with A Brominated Fluoxetine Derivative.
Mono view
Stereo pair view
|
A full contact list of Potassium with other atoms in the K binding
site number 1 of Crystal Structure of Human Two Pore Domain Potassium Ion Channel TREK2 (K2P10.1) in Complex with A Brominated Fluoxetine Derivative. within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:K601
b:0.5
occ:1.00
|
O
|
B:GLY283
|
2.3
|
0.7
|
1.0
|
O
|
A:GLY283
|
2.3
|
0.5
|
1.0
|
O
|
B:GLY174
|
2.8
|
0.3
|
1.0
|
O
|
A:GLY174
|
2.8
|
0.8
|
1.0
|
O
|
A:ILE173
|
2.9
|
0.1
|
1.0
|
O
|
A:VAL282
|
3.0
|
0.2
|
1.0
|
O
|
B:VAL282
|
3.0
|
0.1
|
1.0
|
O
|
B:ILE173
|
3.0
|
96.8
|
1.0
|
C
|
B:GLY283
|
3.4
|
0.6
|
1.0
|
C
|
A:GLY283
|
3.4
|
0.4
|
1.0
|
K
|
B:K401
|
3.4
|
0.9
|
1.0
|
C
|
A:GLY174
|
3.5
|
0.1
|
1.0
|
C
|
B:GLY174
|
3.6
|
0.1
|
1.0
|
O
|
B:TYR175
|
3.9
|
0.2
|
1.0
|
O
|
A:TYR175
|
4.0
|
0.3
|
1.0
|
C
|
A:ILE173
|
4.0
|
0.9
|
1.0
|
CA
|
B:GLY283
|
4.1
|
0.2
|
1.0
|
C
|
A:VAL282
|
4.1
|
0.3
|
1.0
|
CA
|
A:GLY283
|
4.1
|
0.8
|
1.0
|
C
|
B:VAL282
|
4.1
|
0.5
|
1.0
|
CA
|
A:GLY174
|
4.1
|
0.6
|
1.0
|
C
|
B:ILE173
|
4.2
|
97.4
|
1.0
|
N
|
A:TYR175
|
4.2
|
0.7
|
1.0
|
CA
|
B:GLY174
|
4.3
|
95.1
|
1.0
|
N
|
B:TYR175
|
4.3
|
98.8
|
1.0
|
C
|
B:TYR175
|
4.4
|
0.8
|
1.0
|
N
|
B:PHE284
|
4.4
|
0.5
|
1.0
|
C
|
A:TYR175
|
4.4
|
0.4
|
1.0
|
N
|
A:PHE284
|
4.4
|
99.7
|
1.0
|
CA
|
A:TYR175
|
4.5
|
0.8
|
1.0
|
N
|
A:GLY174
|
4.5
|
0.5
|
1.0
|
N
|
B:GLY283
|
4.5
|
0.7
|
1.0
|
N
|
A:GLY283
|
4.5
|
0.2
|
1.0
|
CA
|
B:TYR175
|
4.5
|
99.9
|
1.0
|
N
|
B:GLY174
|
4.7
|
94.9
|
1.0
|
CA
|
B:PHE284
|
4.7
|
0.4
|
1.0
|
CA
|
A:PHE284
|
4.7
|
99.1
|
1.0
|
|
Potassium binding site 2 out
of 6 in 4xdl
Go back to
Potassium Binding Sites List in 4xdl
Potassium binding site 2 out
of 6 in the Crystal Structure of Human Two Pore Domain Potassium Ion Channel TREK2 (K2P10.1) in Complex with A Brominated Fluoxetine Derivative.
Mono view
Stereo pair view
|
A full contact list of Potassium with other atoms in the K binding
site number 2 of Crystal Structure of Human Two Pore Domain Potassium Ion Channel TREK2 (K2P10.1) in Complex with A Brominated Fluoxetine Derivative. within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:K602
b:0.3
occ:1.00
|
O
|
B:THR281
|
2.7
|
0.5
|
1.0
|
OG1
|
A:THR172
|
2.8
|
0.2
|
1.0
|
O
|
A:THR172
|
2.8
|
0.7
|
1.0
|
O
|
B:THR172
|
2.8
|
98.8
|
1.0
|
OG1
|
B:THR172
|
2.9
|
98.8
|
1.0
|
OG1
|
B:THR281
|
2.9
|
0.6
|
1.0
|
O
|
A:THR281
|
3.0
|
0.2
|
1.0
|
OG1
|
A:THR281
|
3.0
|
0.7
|
1.0
|
CB
|
A:THR172
|
3.4
|
0.3
|
1.0
|
CB
|
B:THR281
|
3.5
|
0.9
|
1.0
|
K
|
B:K401
|
3.6
|
0.9
|
1.0
|
CB
|
A:THR281
|
3.6
|
0.8
|
1.0
|
C
|
B:THR281
|
3.7
|
0.5
|
1.0
|
CB
|
B:THR172
|
3.7
|
98.7
|
1.0
|
C
|
A:THR172
|
3.7
|
0.7
|
1.0
|
C
|
B:THR172
|
3.8
|
98.7
|
1.0
|
C
|
A:THR281
|
3.9
|
0.9
|
1.0
|
CA
|
A:THR172
|
4.2
|
0.9
|
1.0
|
CA
|
B:THR281
|
4.2
|
0.8
|
1.0
|
CA
|
B:THR172
|
4.4
|
94.5
|
1.0
|
CA
|
A:THR281
|
4.4
|
0.8
|
1.0
|
CG2
|
A:THR172
|
4.6
|
0.0
|
1.0
|
N
|
B:ILE173
|
4.8
|
94.2
|
1.0
|
CG2
|
B:THR281
|
4.8
|
0.3
|
1.0
|
N
|
B:VAL282
|
4.8
|
0.6
|
1.0
|
N
|
A:ILE173
|
4.9
|
0.6
|
1.0
|
CG2
|
A:THR281
|
4.9
|
0.8
|
1.0
|
O
|
B:THR171
|
4.9
|
0.5
|
1.0
|
O
|
B:THR280
|
5.0
|
0.8
|
1.0
|
CG2
|
B:THR172
|
5.0
|
96.1
|
1.0
|
|
Potassium binding site 3 out
of 6 in 4xdl
Go back to
Potassium Binding Sites List in 4xdl
Potassium binding site 3 out
of 6 in the Crystal Structure of Human Two Pore Domain Potassium Ion Channel TREK2 (K2P10.1) in Complex with A Brominated Fluoxetine Derivative.
Mono view
Stereo pair view
|
A full contact list of Potassium with other atoms in the K binding
site number 3 of Crystal Structure of Human Two Pore Domain Potassium Ion Channel TREK2 (K2P10.1) in Complex with A Brominated Fluoxetine Derivative. within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
B:K401
b:0.9
occ:1.00
|
O
|
A:THR281
|
2.7
|
0.2
|
1.0
|
O
|
B:VAL282
|
2.7
|
0.1
|
1.0
|
O
|
B:ILE173
|
2.8
|
96.8
|
1.0
|
O
|
A:VAL282
|
2.8
|
0.2
|
1.0
|
O
|
A:THR172
|
2.8
|
0.7
|
1.0
|
O
|
B:THR172
|
2.8
|
98.8
|
1.0
|
O
|
B:THR281
|
2.8
|
0.5
|
1.0
|
O
|
A:ILE173
|
2.9
|
0.1
|
1.0
|
K
|
A:K601
|
3.4
|
0.5
|
1.0
|
C
|
B:ILE173
|
3.4
|
97.4
|
1.0
|
C
|
B:VAL282
|
3.5
|
0.5
|
1.0
|
C
|
A:VAL282
|
3.6
|
0.3
|
1.0
|
C
|
A:ILE173
|
3.6
|
0.9
|
1.0
|
K
|
A:K602
|
3.6
|
0.3
|
1.0
|
C
|
A:THR281
|
3.8
|
0.9
|
1.0
|
C
|
B:THR172
|
3.8
|
98.7
|
1.0
|
C
|
A:THR172
|
3.9
|
0.7
|
1.0
|
CA
|
B:ILE173
|
3.9
|
93.2
|
1.0
|
C
|
B:THR281
|
3.9
|
0.5
|
1.0
|
CA
|
A:ILE173
|
4.0
|
0.2
|
1.0
|
CA
|
A:VAL282
|
4.0
|
98.6
|
1.0
|
CA
|
B:VAL282
|
4.1
|
0.3
|
1.0
|
N
|
B:ILE173
|
4.3
|
94.2
|
1.0
|
N
|
A:VAL282
|
4.4
|
0.8
|
1.0
|
N
|
A:ILE173
|
4.4
|
0.6
|
1.0
|
N
|
B:GLY283
|
4.4
|
0.7
|
1.0
|
N
|
B:GLY174
|
4.4
|
94.9
|
1.0
|
N
|
B:VAL282
|
4.4
|
0.6
|
1.0
|
N
|
A:GLY174
|
4.5
|
0.5
|
1.0
|
N
|
A:GLY283
|
4.5
|
0.2
|
1.0
|
O
|
B:GLY283
|
4.7
|
0.7
|
1.0
|
CA
|
B:GLY283
|
4.8
|
0.2
|
1.0
|
O
|
A:GLY283
|
4.8
|
0.5
|
1.0
|
CA
|
A:GLY283
|
4.9
|
0.8
|
1.0
|
CA
|
A:GLY174
|
4.9
|
0.6
|
1.0
|
CA
|
B:GLY174
|
4.9
|
95.1
|
1.0
|
CA
|
A:THR281
|
5.0
|
0.8
|
1.0
|
|
Potassium binding site 4 out
of 6 in 4xdl
Go back to
Potassium Binding Sites List in 4xdl
Potassium binding site 4 out
of 6 in the Crystal Structure of Human Two Pore Domain Potassium Ion Channel TREK2 (K2P10.1) in Complex with A Brominated Fluoxetine Derivative.
Mono view
Stereo pair view
|
A full contact list of Potassium with other atoms in the K binding
site number 4 of Crystal Structure of Human Two Pore Domain Potassium Ion Channel TREK2 (K2P10.1) in Complex with A Brominated Fluoxetine Derivative. within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
C:K601
b:0.8
occ:1.00
|
O
|
C:GLY283
|
2.3
|
0.3
|
1.0
|
O
|
D:GLY283
|
2.4
|
0.5
|
1.0
|
O
|
D:GLY174
|
2.8
|
0.3
|
1.0
|
O
|
C:GLY174
|
2.8
|
0.1
|
1.0
|
O
|
C:ILE173
|
2.8
|
0.2
|
1.0
|
O
|
D:ILE173
|
2.9
|
0.4
|
1.0
|
O
|
C:VAL282
|
2.9
|
0.4
|
1.0
|
O
|
D:VAL282
|
3.0
|
0.5
|
1.0
|
C
|
C:GLY283
|
3.4
|
0.0
|
1.0
|
C
|
D:GLY174
|
3.4
|
0.1
|
1.0
|
C
|
C:GLY174
|
3.4
|
0.9
|
1.0
|
K
|
C:K602
|
3.4
|
0.1
|
1.0
|
C
|
D:GLY283
|
3.5
|
0.6
|
1.0
|
O
|
C:TYR175
|
3.9
|
0.1
|
1.0
|
C
|
C:ILE173
|
4.0
|
0.3
|
1.0
|
O
|
D:TYR175
|
4.0
|
0.4
|
1.0
|
C
|
C:VAL282
|
4.0
|
0.3
|
1.0
|
C
|
D:ILE173
|
4.1
|
0.3
|
1.0
|
CA
|
C:GLY283
|
4.1
|
0.8
|
1.0
|
C
|
D:VAL282
|
4.1
|
0.1
|
1.0
|
CA
|
D:GLY283
|
4.1
|
0.3
|
1.0
|
N
|
C:TYR175
|
4.2
|
0.3
|
1.0
|
CA
|
D:GLY174
|
4.2
|
0.1
|
1.0
|
CA
|
C:GLY174
|
4.2
|
0.3
|
1.0
|
N
|
D:TYR175
|
4.2
|
0.8
|
1.0
|
C
|
C:TYR175
|
4.4
|
0.2
|
1.0
|
C
|
D:TYR175
|
4.4
|
0.1
|
1.0
|
CA
|
C:TYR175
|
4.4
|
0.1
|
1.0
|
N
|
C:PHE284
|
4.4
|
0.5
|
1.0
|
CA
|
D:TYR175
|
4.5
|
0.6
|
1.0
|
N
|
C:GLY283
|
4.5
|
0.0
|
1.0
|
N
|
C:GLY174
|
4.5
|
0.8
|
1.0
|
N
|
D:PHE284
|
4.5
|
0.6
|
1.0
|
N
|
D:GLY174
|
4.5
|
0.8
|
1.0
|
N
|
D:GLY283
|
4.5
|
0.8
|
1.0
|
CA
|
C:PHE284
|
4.7
|
0.9
|
1.0
|
CA
|
D:PHE284
|
4.8
|
0.6
|
1.0
|
|
Potassium binding site 5 out
of 6 in 4xdl
Go back to
Potassium Binding Sites List in 4xdl
Potassium binding site 5 out
of 6 in the Crystal Structure of Human Two Pore Domain Potassium Ion Channel TREK2 (K2P10.1) in Complex with A Brominated Fluoxetine Derivative.
Mono view
Stereo pair view
|
A full contact list of Potassium with other atoms in the K binding
site number 5 of Crystal Structure of Human Two Pore Domain Potassium Ion Channel TREK2 (K2P10.1) in Complex with A Brominated Fluoxetine Derivative. within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
C:K602
b:0.1
occ:1.00
|
O
|
D:THR281
|
2.6
|
0.7
|
1.0
|
O
|
C:THR281
|
2.7
|
0.6
|
1.0
|
O
|
C:ILE173
|
2.7
|
0.2
|
1.0
|
O
|
C:THR172
|
2.7
|
0.9
|
1.0
|
O
|
D:ILE173
|
2.8
|
0.4
|
1.0
|
O
|
C:VAL282
|
2.8
|
0.4
|
1.0
|
O
|
D:VAL282
|
2.8
|
0.5
|
1.0
|
O
|
D:THR172
|
2.9
|
1.0
|
1.0
|
K
|
C:K603
|
3.4
|
0.5
|
1.0
|
C
|
C:ILE173
|
3.4
|
0.3
|
1.0
|
K
|
C:K601
|
3.4
|
0.8
|
1.0
|
C
|
D:ILE173
|
3.5
|
0.3
|
1.0
|
C
|
C:VAL282
|
3.5
|
0.3
|
1.0
|
C
|
D:VAL282
|
3.6
|
0.1
|
1.0
|
C
|
C:THR281
|
3.8
|
0.7
|
1.0
|
C
|
D:THR281
|
3.8
|
0.5
|
1.0
|
C
|
C:THR172
|
3.8
|
0.1
|
1.0
|
CA
|
C:ILE173
|
3.8
|
0.1
|
1.0
|
C
|
D:THR172
|
3.9
|
0.4
|
1.0
|
CA
|
D:ILE173
|
4.0
|
0.6
|
1.0
|
CA
|
C:VAL282
|
4.0
|
0.4
|
1.0
|
CA
|
D:VAL282
|
4.1
|
0.6
|
1.0
|
N
|
C:ILE173
|
4.3
|
0.6
|
1.0
|
N
|
C:VAL282
|
4.3
|
0.0
|
1.0
|
N
|
D:VAL282
|
4.4
|
0.4
|
1.0
|
N
|
D:ILE173
|
4.4
|
0.6
|
1.0
|
N
|
C:GLY174
|
4.4
|
0.8
|
1.0
|
N
|
D:GLY174
|
4.4
|
0.8
|
1.0
|
N
|
C:GLY283
|
4.5
|
0.0
|
1.0
|
N
|
D:GLY283
|
4.5
|
0.8
|
1.0
|
O
|
C:GLY283
|
4.8
|
0.3
|
1.0
|
O
|
D:GLY283
|
4.9
|
0.5
|
1.0
|
CA
|
C:GLY283
|
4.9
|
0.8
|
1.0
|
CA
|
D:GLY174
|
4.9
|
0.1
|
1.0
|
CA
|
C:GLY174
|
4.9
|
0.3
|
1.0
|
CA
|
C:THR281
|
4.9
|
0.7
|
1.0
|
CA
|
D:THR281
|
5.0
|
0.8
|
1.0
|
CA
|
D:GLY283
|
5.0
|
0.3
|
1.0
|
|
Potassium binding site 6 out
of 6 in 4xdl
Go back to
Potassium Binding Sites List in 4xdl
Potassium binding site 6 out
of 6 in the Crystal Structure of Human Two Pore Domain Potassium Ion Channel TREK2 (K2P10.1) in Complex with A Brominated Fluoxetine Derivative.
Mono view
Stereo pair view
|
A full contact list of Potassium with other atoms in the K binding
site number 6 of Crystal Structure of Human Two Pore Domain Potassium Ion Channel TREK2 (K2P10.1) in Complex with A Brominated Fluoxetine Derivative. within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
C:K603
b:0.5
occ:1.00
|
O
|
C:THR172
|
2.4
|
0.9
|
1.0
|
OG1
|
C:THR172
|
2.6
|
0.8
|
1.0
|
OG1
|
D:THR281
|
2.8
|
0.1
|
1.0
|
O
|
D:THR281
|
2.8
|
0.7
|
1.0
|
O
|
C:THR281
|
2.9
|
0.6
|
1.0
|
O
|
D:THR172
|
2.9
|
1.0
|
1.0
|
OG1
|
C:THR281
|
3.1
|
0.3
|
1.0
|
CB
|
C:THR172
|
3.3
|
0.3
|
1.0
|
OG1
|
D:THR172
|
3.4
|
0.3
|
1.0
|
K
|
C:K602
|
3.4
|
0.1
|
1.0
|
C
|
C:THR172
|
3.4
|
0.1
|
1.0
|
CB
|
D:THR281
|
3.4
|
0.5
|
1.0
|
CB
|
C:THR281
|
3.5
|
0.2
|
1.0
|
C
|
D:THR281
|
3.6
|
0.5
|
1.0
|
C
|
C:THR281
|
3.9
|
0.7
|
1.0
|
CA
|
C:THR172
|
4.0
|
0.3
|
1.0
|
C
|
D:THR172
|
4.0
|
0.4
|
1.0
|
CB
|
D:THR172
|
4.0
|
0.8
|
1.0
|
CA
|
D:THR281
|
4.2
|
0.8
|
1.0
|
CA
|
C:THR281
|
4.3
|
0.7
|
1.0
|
N
|
C:ILE173
|
4.5
|
0.6
|
1.0
|
CG2
|
C:THR172
|
4.6
|
0.7
|
1.0
|
CA
|
D:THR172
|
4.7
|
0.9
|
1.0
|
N
|
D:VAL282
|
4.7
|
0.4
|
1.0
|
CG2
|
C:THR281
|
4.7
|
0.6
|
1.0
|
CG2
|
D:THR281
|
4.7
|
0.1
|
1.0
|
O
|
C:THR171
|
4.7
|
0.0
|
1.0
|
O
|
D:THR280
|
4.8
|
0.9
|
1.0
|
CA
|
C:ILE173
|
4.9
|
0.1
|
1.0
|
N
|
D:ILE173
|
5.0
|
0.6
|
1.0
|
N
|
C:VAL282
|
5.0
|
0.0
|
1.0
|
|
Reference:
A.C.W.Pike,
A.Mackenzie,
C.Mcclenaghan,
P.Aryal,
L.Dong,
A.Quigley,
M.Grieben,
S.Goubin,
S.Mukhopadhyay,
G.F.Ruda,
M.V.Clausen,
L.Cao,
P.E.Brennan,
N.A.Burgess-Brown,
M.S.P.Sansom,
S.J.Tucker,
E.P.Carpenter.
K2P Channel Gating Mechanisms Revealed By Structures of Trek-2 and A Complex with Prozac Science V. 347 2015.
ISSN: ESSN 1095-9203
DOI: 10.1126/SCIENCE.1261512
Page generated: Mon Aug 12 12:31:56 2024
|